PMID: 11919237Mar 29, 2002Paper

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Francisco J EstevaGabriel N Hortobagyi

Abstract

To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels. Thirty women with metastatic breast cancer were treated with weekly docetaxel and trastuzumab as first- or second-line therapy. Both docetaxel 35 mg/m(2)/wk and trastuzumab 2 mg/kg/wk were delivered in 4-week cycles consisting of three weekly treatments followed by 1 week of rest. A loading dose of trastuzumab 4 mg/kg was administered 1 day before the start of the first cycle. The median delivered dose-intensity of docetaxel was 24 mg/m(2)/wk (range, 18 to 27 mg/m(2)/wk). The intent-to-treat overall response rate (ORR) was 63% (95% confidence interval [CI], 44% to 80%). The ORR in patients whose tumors were HER-2-positive by fluorescence in situ hybridization was 67% (16 of 24 patients; 95% CI, 45% to 84%). In patients with elevated serum HER-2 ECD at baseline, the ORR was 76% (95% CI, 53% to 92%), compared with 33% (95% CI, 7% to 70%) in patients with low HER-2 ECD levels (P =.04). Variations in HER-2 ECD concentrations during treatment correlated with response to treatment. Median time to progression was 9 months. Acute...Continue Reading

References

Jun 14, 1991·Clinica Chimica Acta; International Journal of Clinical Chemistry·S M D'AmbrosioR W Trewyn
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K LeitzelA Lipton
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M RavdinR E Bellet
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V ValeroG N Hortobagyi
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaL Norton
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H YamauchiD F Hayes
Jan 1, 1997·Acta Oncologica·F J Esteva-LorenzoL N Harris
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I L AndrulisD McCready
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T W JacobsS J Schnitt
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S ChanUNKNOWN 303 Study Group
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H J BursteinE P Winer
May 9, 2000·American Journal of Clinical Pathology·R VangJ Abrams
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B C Pestalozzi, S Brignoli
Apr 13, 2001·Seminars in Oncology·H A Burris
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanC A Hudis
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H J BursteinE P Winer
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Dec 26, 2001·Archives of Ophthalmology·M A Ahmadi, B Esmaeli

❮ Previous
Next ❯

Citations

May 19, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Alberto OcañaJuan J Cruz
Jan 15, 2003·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Katsumasa KuroiMasakazu Toi
Nov 20, 2004·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Akemi KataokaShinji Ohno
Mar 11, 2006·Cancer Chemotherapy and Pharmacology·Hugo E R FordStephen R D Johnston
Jul 20, 2006·International Journal of Clinical Oncology·Eriko TokunagaYoshihiko Maehara
Jan 7, 2011·International Journal of Clinical Oncology·Naoki HayashiNaoto T Ueno
May 25, 2011·International Journal of Clinical Oncology·Naoki HayashiNaoto T Ueno
Apr 26, 2008·Breast Cancer Research and Treatment·Vivien H C BramwellAnn F Chambers
Aug 5, 2008·Breast Cancer Research and Treatment·Maysa M Abu-Khalaf, Lyndsay Harris
Dec 12, 2012·Breast Cancer Research and Treatment·Kenneth R Hess, Francisco J Esteva
Sep 1, 2005·Investigational New Drugs·Christina H Yeon, Mark D Pegram
Mar 5, 2009·Journal of Mammary Gland Biology and Neoplasia·Philippe L BedardMartine J Piccart-Gebhart
Oct 12, 2012·Journal of Mammary Gland Biology and Neoplasia·Yuzhe Yang, Douglas Yee
Mar 28, 2008·Current Oncology Reports·Alice Ulhoa-CintraCharles E Geyer
Dec 16, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·R ColomerH Cortés-Funes
Apr 13, 2004·Clinical Oncology : a Journal of the Royal College of Radiologists·P K JulkaG K Rath
May 18, 2004·Cancer Treatment Reviews·Hans Wildiers, Robert Paridaens
May 5, 2004·Gynécologie, obstétrique & fertilité·P Beuzeboc
Jun 18, 2003·Clinical Biochemistry·Diana LüftnerKurt Possinger
Sep 16, 2003·Cancer Treatment Reviews·Roy S Herbst, Fadlo R Khuri
Mar 9, 2013·Cell Death & Disease·Y ZhaoM Tan
May 10, 2006·Nature Clinical Practice. Oncology·Rita NahtaFrancisco J Esteva
Dec 25, 2008·Nature Clinical Practice. Oncology·Gabriella MarianiLuca Gianni
Dec 23, 2009·Nature Reviews. Clinical Oncology·Francisco J EstevaGabriel N Hortobagyi
Nov 16, 2011·Nature Reviews. Clinical Oncology·Miriam MartiniAlberto Bardelli
May 29, 2007·Oncogene·I Zafir-LavieY Reiter
May 29, 2007·Oncogene·R Nahta, F J Esteva
Aug 6, 2008·The Pharmacogenomics Journal·O N Ikediobi
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Apr 8, 2011·The Journal of Biological Chemistry·Chang GongErwei Song
Jul 22, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Esparís-OgandoA Pandiella
Aug 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V HeinemannH J Stemmler
Apr 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S M TolaneyI E Krop
May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
Jan 10, 2013·Journal of the National Cancer Institute·Rinki JainJon A Weidanz
Feb 8, 2006·American Journal of Clinical Oncology·Alberto OcañaAtanasio Pandiella
Apr 9, 2010·Anti-cancer Drugs·Sandra GeigerHans-Joachim Stemmler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved